Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Abstract

Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle-aged males between the ages of 45 and 60 years, and is the highest cause of cancer-associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N 6 -methyladenosine (m 6 A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expression levels of various m 6 A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m 6 A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m 6 A methylation modification in PCa. It is considered that the treatment of PCa with micro-molecular drugs that target the epigenetics of the m 6 A regulator to correct abnormal m 6 A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.

Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches

“…However, approximately 30% of PCa cases progress to metastatic disease, with bone metastases being the most prevalent in advanced cases [ 3 ]. The five-year survival rate for advanced metastatic PCa is only around 28% [ 4 ]. Since a significant portion of PCa cell growth relies on androgen receptor (AR) signaling, androgen deprivation therapy (ADT) remains the primary clinical treatment for advanced PCa [ 5 ].…”